Coriolis Pharma Excels with TOP10 Listed Articles in JPharmSci
|| Print ||
|Tuesday, 05 June 2012 14:45 (UTC + 2)|
Scientific excellence in biopharmaceutical contract research for protein formulation development, aggregation analysis and particle characterization
Martinsried/Munich, Germany, June 5, 2012 / B3C newswire / - Coriolis Pharma staff and scientific advisory board members are pleased to announce that they hold three positions in the JPharmSci TOP10 of most downloaded publications.
JPharmSci allows free download of the TOP10 papers until end of June including three papers with involvement from Coriolis Pharma:
Forced degradation of therapeutic proteins
Particles in therapeutic protein formulations, Part 1: Overview of analytical methods
Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release
More highly relevant publications from Coriolis Pharma related to protein aggregation analysis, particle characterization and formulation development for biopharmaceuticals can be found on http://www.coriolis-pharma.com/publications.html.
About Coriolis Pharma
An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals supported by an expert scientific advisory board provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals.
This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing (light obscuration, Micro-Flow Imaging and AF4/HF5 under cGMP), supply of pre-clinical material, and innovative analytical technologies for aggregate analysis and particle characterization.
Dr. Michael Wiggenhorn, CEO